GlobalData on MSN5d
Priority FDA review given to AstraZeneca’s Imfinzi sBLA for MIBC
The US Food and Drug Administration (FDA) has granted priority review to AstraZeneca's supplemental biologics licence ...
gh.bmj10d
The priority review voucher: a misconceived quid pro quo
Various ‘push-and-pull’ mechanisms have been tried to attract pharmaceutical companies into medical innovation for public ...
Business Wire2d
Acadia Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the closing of the sale of its Rare Pediatric Disease Priority ...
After Lung Cancer Approval, AstraZeneca's Imfinzi Goes Under FDA Priority Review For Bladder Cancer
AstraZeneca's Imfinzi gains FDA Priority Review for bladder cancer. Key trial data shows improved survival and progression ...
Monthly Prescribing Reference8d
Durvalumab Gets Priority Review for Muscle-Invasive Bladder Cancer
The Food and Drug Administration (FDA) has granted Priority Review to durvalumab for the treatment of adults with muscle-invasive bladder cancer (MIBC). The coprimary endpoints were pathological ...
Targeted Oncology7d
FDA Grants Priority Review to Durvalumab in MIBC
If approved, durvalumab will be the first and only perioperative immunotherapy regimen available for the treatment of ...
Yahoo Finance7d
IMFINZI® (durvalumab) granted Priority Review in the US for patients with muscle-invasive bladder cancer
December 06, 2024--(BUSINESS WIRE)--AstraZeneca’s supplemental Biologics License Application (sBLA) for IMFINZI ® (durvalumab) has been accepted and granted Priority Review in the US for the ...
Stop non-priority spending, Treasury warns ministers
Ministers have been told to stop spending that does not contribute to the government's priorities, as Chancellor Rachel ...
Yahoo Finance5d
Priority FDA review given to AstraZeneca’s Imfinzi sBLA for MIBC
The US Food and Drug Administration (FDA) has granted priority review to AstraZeneca's supplemental biologics licence application (sBLA) for Imfinzi (durvalumab), a human monoclonal antibody ...